Novantrone (Mitoxantrone Hydrochloride)

Mitoxantrone Hydrochloride, the active ingredient in Novantrone, is an anthracenedone presented as an intravenous formulation for use in oncology and neurology. It is employed in the treatment of acute myeloid leukemia, prostate and breast cancers, as well as multiple sclerosis, providing cytotoxic activity against rapidly dividing cells.

GNH USA supplies Novantrone as a licensed, GDP‑compliant international pharmaceutical supplier, providing quality‑assured batches to hospitals, oncology centres, transplant units and specialty pharmacies worldwide, with support for regulatory documentation and cold‑chain logistics and timely.

Novantrone is indicated for several malignancies and an autoimmune condition, targeting rapidly proliferating cells.

Acute myeloid leukemia: induces remission by causing DNA damage in leukemic blasts. Prostate cancer: reduces tumor burden and may improve survival in advanced disease. Breast cancer: provides cytotoxic effect in metastatic or refractory cases. Multiple sclerosis: decreases disease activity by modulating immune cell proliferation.

Novantrone may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Fatigue - Alopecia - Myelosuppression (low blood counts) - Mucositis

Serious or Rare Side Effects: - Cardiotoxicity (reduced left ventricular function) - Secondary acute leukemia - Severe infections - Hepatic toxicity

Prior to initiating Novantrone, clinicians should evaluate several safety parameters and monitor patients throughout therapy.

- Blood counts: monitor complete blood count regularly to detect myelosuppression. - Cardiac function: assess baseline and periodic ejection fraction due to risk of cardiotoxicity. - Liver enzymes: evaluate hepatic function before and during treatment. - Infection risk: avoid use in patients with active severe infections. - Renal function: adjust monitoring in impaired renal clearance. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Novantrone can interact with other medicines, affecting efficacy or toxicity.

Major Interactions (Avoid): - Anthracyclines: concurrent use increases risk of cardiotoxicity. - Live vaccines: immunosuppression may lead to uncontrolled infection. - High‑dose radiation: combined therapy may exacerbate tissue damage.

Moderate Interactions (Monitor Closely): - CYP2C8 inhibitors (e.g., gemfibrozil): may raise plasma levels of Mitoxantrone. - Anticoagulants: increased bleeding risk. - NSAIDs: may worsen renal impairment.